Oric Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oric Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q3 2024.
  • Oric Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $5.06M, a 30.8% increase year-over-year.
  • Oric Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $18.9M, a 31.2% increase year-over-year.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $15.2M, a 5.3% increase from 2022.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $14.5M, a 12.5% increase from 2021.
  • Oric Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12.9M, a 144% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $18.9M $5.06M +$1.19M +30.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $17.7M $5M +$1.17M +30.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $16.6M $4.96M +$1.34M +37.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $15.2M $3.92M +$793K +25.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 $14.4M $3.86M +$571K +17.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $13.9M $3.83M -$267K -6.53% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $14.1M $3.61M -$331K -8.39% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $14.5M $3.13M -$369K -10.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 $14.8M $3.29M -$104K -3.06% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $14.9M $4.09M +$879K +27.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $14.1M $3.95M +$1.2M +43.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $12.9M $3.5M +$1.81M +107% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $11M $3.4M +$1.72M +102% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $9.33M $3.21M +$1.83M +133% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $7.5M $2.74M +$2.22M +421% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $5.28M $1.69M +$1.26M +290% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 $4.02M $1.68M +$1.41M +520% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $2.61M $1.38M +$1.19M +627% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $1.42M $527K +$327K +164% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $1.09M $433K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-21
Q3 2019 $271K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $190K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $200K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.